Join Our Mailing List:
 
Follow Us:
Shop Contact Us
You have 0  Item in Cart | View Cart
310-841-2600
Featured Events
View All Events
Alex Herrera, M.D.
Research performed at: City of Hope Comprehensive Cancer Center
Specialty/Research Area: Lymphoma
Award Year: 2018
Career Summary: Dr. Alex Herrera is an Assistant Professor in the Department of hematology and hematopoietic Cell Transplantation at City of Hope National Medical Center. Dr. Herrera received his medical degree from Harvard Medical School (Boston, MA) and completed his residency in internal medicine at the Brigham and Women’s Hospital, before pursuing a hematology-oncology fellowship at the Dana-Farber Cancer Institute/Massachusetts General Hospital. In addition to his STOP CANCER Award, Dr. Herrera is the recipient of several awards including the American Society of Clinical Oncology/Conquer Cancer Foundation Young Investigator Award (2014), the American Society of Blood and Marrow Transplantation/Biology of Blood and Marrow Transplantation George Santos Award for Best Clinical Science Article by a New Investigator (2015), City of Hope K12 Paul Calabresi Career Development Award for Clinical Oncology (2015), the SWOG Integrated Translational Science Center Pilot Award (2017-2018), and the lymphoma Research Foundation Larry and Denise Mason Clinical Investigator Career Development Award (2017-2020).

Year STOP CANCER Award was received: 2018 Wiviott Wish Seed Grant in memory of Robert Nelson Wiviott

Description of research performed: lymphomas are the most common type of blood cancer and include Hodgkin and non-Hodgkin disease. Dr. Herrera's clinical and research interests center on immunotherapy and hematopoietic stem cell transplantation in patients with lymphoma

Results of research: Dr. Herrera is currently leading more than 15 clinical trials evaluating immune checkpoint inhibitors, adoptive cellular therapies, and other novel agents for the treatment of patients with newly diagnosed or relapsed/refractory non-Hodgkin lymphoma, classical Hodgkin lymphoma, and in lymphoma patients undergoing hematopoietic stem cell transplantation. In addition to developing novel immunotherapy combinations, Dr. Herrera studies biomarkers of response and outcome in patients with lymphoma treated with immunotherapies or hematopoietic stem cell transplantation. His current research evaluates immunohistochemical and cytogenetic biomarkers, sequencing-based circulating tumor DNA detection, as well as gene expression, mutational profiling and quantitative spatial immunofluorescence of tumor cells and the tumor microenvironment to identify biomarkers predictive of response to a treatment. The goal of these studies is to identify the patient populations most likely to benefit from a therapy to improve outcomes.

STOP CANCER is committed to funding the most promising and innovative scientists in their early research of all forms of cancer prevention, treatment, cures and subsequent clinical applications. STOP CANCER works primarily with local National Cancer Institute-designated Comprehensive Cancer Centers and other qualified institutions in the United States to carry out its mission.

Copyright © 2018 STOP CANCER. All Rights Reserved. | Privacy Policy